| Stereochemistry | ABSOLUTE |
| Molecular Formula | 5C88H100Cl2N10O28.8ClH |
| Molecular Weight | 9375.147 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 90 / 90 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.Cl.Cl.Cl.Cl.Cl.Cl.CN[C@@H]1C2=CC(OC3=CC(O)=C(Cl)C(=C3)[C@@H]4NC(=O)[C@@H](CC5=CC=C(OC6=C(O[C@@H]7O[C@@H]([C@@H](O)[C@H](O)[C@H]7NC(=O)CCCCCCCCC(C)C)C(O)=O)C8=CC(=C6)[C@@H](NC4=O)C(=O)N[C@@H]9C%10=CC=C(O)C(=C%10)C%11=C(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]%12O)C=C(O)C=C%11[C@H](NC(=O)[C@@H](NC9=O)[C@H](O)C%13=CC=C(O8)C(Cl)=C%13)C(=O)NCCCN(C)C)C=C5)NC1=O)=C(O)C=C2.CN[C@@H]%14C%15=CC(OC%16=CC(O)=C(Cl)C(=C%16)[C@@H]%17NC(=O)[C@@H](CC%18=CC=C(OC%19=C(O[C@@H]%20O[C@@H]([C@@H](O)[C@H](O)[C@H]%20NC(=O)CCCCCCCCC(C)C)C(O)=O)C%21=CC(=C%19)[C@@H](NC%17=O)C(=O)N[C@@H]%22C%23=CC=C(O)C(=C%23)C%24=C(O[C@H]%25O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]%25O)C=C(O)C=C%24[C@H](NC(=O)[C@@H](NC%22=O)[C@H](O)C%26=CC=C(O%21)C(Cl)=C%26)C(=O)NCCCN(C)C)C=C%18)NC%14=O)=C(O)C=C%15.CN[C@@H]%27C%28=CC(OC%29=CC(O)=C(Cl)C(=C%29)[C@@H]%30NC(=O)[C@@H](CC%31=CC=C(OC%32=C(O[C@@H]%33O[C@@H]([C@@H](O)[C@H](O)[C@H]%33NC(=O)CCCCCCCCC(C)C)C(O)=O)C%34=CC(=C%32)[C@@H](NC%30=O)C(=O)N[C@@H]%35C%36=CC=C(O)C(=C%36)C%37=C(O[C@H]%38O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]%38O)C=C(O)C=C%37[C@H](NC(=O)[C@@H](NC%35=O)[C@H](O)C%39=CC=C(O%34)C(Cl)=C%39)C(=O)NCCCN(C)C)C=C%31)NC%27=O)=C(O)C=C%28.CN[C@@H]%40C%41=CC(OC%42=CC(O)=C(Cl)C(=C%42)[C@@H]%43NC(=O)[C@@H](CC%44=CC=C(OC%45=C(O[C@@H]%46O[C@@H]([C@@H](O)[C@H](O)[C@H]%46NC(=O)CCCCCCCCC(C)C)C(O)=O)C%47=CC(=C%45)[C@@H](NC%43=O)C(=O)N[C@@H]%48C%49=CC=C(O)C(=C%49)C%50=C(O[C@H]%51O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]%51O)C=C(O)C=C%50[C@H](NC(=O)[C@@H](NC%48=O)[C@H](O)C%52=CC=C(O%47)C(Cl)=C%52)C(=O)NCCCN(C)C)C=C%44)NC%40=O)=C(O)C=C%41.CN[C@@H]%53C%54=CC(OC%55=CC(O)=C(Cl)C(=C%55)[C@@H]%56NC(=O)[C@@H](CC%57=CC=C(OC%58=C(O[C@@H]%59O[C@@H]([C@@H](O)[C@H](O)[C@H]%59NC(=O)CCCCCCCCC(C)C)C(O)=O)C%60=CC(=C%58)[C@@H](NC%56=O)C(=O)N[C@@H]%61C%62=CC=C(O)C(=C%62)C%63=C(O[C@H]%64O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]%64O)C=C(O)C=C%63[C@H](NC(=O)[C@@H](NC%61=O)[C@H](O)C%65=CC=C(O%60)C(Cl)=C%65)C(=O)NCCCN(C)C)C=C%57)NC%53=O)=C(O)C=C%54
InChI
InChIKey=ALCMRBLIJBFSAZ-XERKAGHASA-N
InChI=1S/5C88H100Cl2N10O28.8ClH/c5*1-38(2)13-10-8-6-7-9-11-14-61(106)94-70-73(109)75(111)78(86(120)121)128-87(70)127-77-58-31-43-32-59(77)124-55-24-19-42(29-50(55)89)71(107)69-85(119)98-67(80(114)92-25-12-26-100(4)5)48-33-44(102)34-57(125-88-76(112)74(110)72(108)60(37-101)126-88)62(48)47-28-40(17-22-52(47)103)65(82(116)99-69)95-83(117)66(43)96-84(118)68-49-35-46(36-54(105)63(49)90)123-56-30-41(18-23-53(56)104)64(91-3)81(115)93-51(79(113)97-68)27-39-15-20-45(122-58)21-16-39;;;;;;;;/h5*15-24,28-36,38,51,60,64-76,78,87-88,91,101-105,107-112H,6-14,25-27,37H2,1-5H3,(H,92,114)(H,93,115)(H,94,106)(H,95,117)(H,96,118)(H,97,113)(H,98,119)(H,99,116)(H,120,121);8*1H/t5*51-,60-,64-,65-,66-,67+,68+,69+,70-,71-,72-,73-,74+,75+,76+,78+,87-,88+;;;;;;;;/m11111......../s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
MOL RATIO
8 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C88H100Cl2N10O28 |
| Molecular Weight | 1816.692 |
| Charge | 0 |
| Count |
MOL RATIO
5 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 18 / 18 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Dalbavancin is a mixture of five closely related active homologs (A0, A1, B0, B1, and B2); the component B0 is the major component of dalbavancin. The predominant component of dalbavancin is Factor B0, which accounts for >75% of the whole complex. Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin. Modifications from these older glycoprotein classes allowed a similar mechanism of action with increased activity and once weekly dosing. Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), S. pyogenes, S. agalactiae, and S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus). Under the brand name DALVANCE Dalbavancin is indicated for acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms. The bactericidal action of dalbavancin results primarily from inhibition of cell-wall biosynthesis. Specifically, dalbavancin prevents incorporation of N-acetylmuramic acid (NAM)- and N-acetylglucosamine (NAG)-peptide subunits from being incorporated into the peptidoglycan matrix; which forms the major structural component of Gram-positive cell walls. The large hydrophilic molecule is able to form hydrogen bond interactions with the terminal D-alanyl-D-alanine moieties of the NAM/NAG-peptides, which is normally a five-point interaction. Binding of dalbavancin to the D-Ala-D-Ala prevents the incorporation of the NAM/NAG-peptide subunits into the peptidoglycan matrix. In addition, dalbavancin alters bacterial-cell-membrane permeability and RNA synthesis.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
1. Two-dose regimen: 1000 mg followed one week later by 500 mg (2.1)
2. Dosage adjustment for patients with creatinine clearance less than 30
mL/min and not receiving regularly scheduled hemodialysis: 750 mg
followed one week later by 375 mg (2.2)
3. Administer by intravenous infusion over 30 minutes (2.3)
Route of Administration:
Intravenous
